

Matthew D Hellmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3674496/publications.pdf>

Version: 2024-02-01

161
papers

62,631
citations

5896

81
h-index

7348

152
g-index

167
all docs

167
docs citations

167
times ranked

53133
citing authors

#	ARTICLE	IF	CITATIONS
1	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	1.1	173
2	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
3	Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2022, 167, 158-164.	0.6	10
4	Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor types. <i>Immunity</i> , 2022, 55, 56-64.e4.	14.3	19
5	First-Line Immunotherapy for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 586-597.	1.6	312
6	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. <i>Journal of Thoracic Oncology</i> , 2022, 17, 661-674.	1.1	9
7	TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	64
8	Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers. <i>British Journal of Cancer</i> , 2022, 126, 889-898.	6.4	8
9	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 1450-1459.	2.5	10
10	Fundamental immune oncogenicity trade-offs define driver mutation fitness. <i>Nature</i> , 2022, 606, 172-179.	27.8	23
11	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. , 2022, 10, e003956.		16
12	Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	8
13	Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer. , 2022, 10, e004440.		49
14	Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥5%) Tj ETQg0 0 0 rgBT /Overlo	1.8	8
15	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	7.1	117
16	Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3797-3803.	7.0	15
17	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 1019-1028.	7.0	58
18	Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. <i>Cancer Discovery</i> , 2021, 11, 59-67.	9.4	38

#	ARTICLE	IF	CITATIONS
19	Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2773-2781.	7.0	55
20	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12Câ€“Mutant Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2209-2215.	7.0	65
21	Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. , 2021, 9, e001884.		27
22	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14.	28.9	485
23	Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9016-9016.	1.6	25
24	Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child. <i>Nature Medicine</i> , 2021, 27, 1646-1654.	30.7	65
25	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021, 151, 211-220.	2.8	24
26	Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100197.	1.1	3
27	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ Tâ€“cell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.	16.8	93
28	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5131-5140.	7.0	40
29	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132.	27.8	234
30	Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research. <i>Cancer Cell</i> , 2021, 39, 897-899.	16.8	1
31	The Impact of Durvalumab on Local-Regional Control in Stage III NSCLCs Treated With Chemoradiation and on KEAP1-NFE2L2-Mutant Tumors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1392-1402.	1.1	12
32	Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1759-1764.	1.1	49
33	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. <i>Annals of Oncology</i> , 2021, 32, 1626-1636.	1.2	86
34	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. <i>Lung Cancer</i> , 2021, 161, 60-67.	2.0	2
35	First-in-Humans Imaging with ⁸⁹ Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. <i>Journal of Nuclear Medicine</i> , 2020, 61, 512-519.	5.0	170
36	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020, 15, 426-435.	1.1	181

#	ARTICLE	IF	CITATIONS
37	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020, 10, 40-53.	9.4	219
38	Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 144, 101-104.	0.6	21
39	Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERA-VOLT Experience. <i>Cancer Cell</i> , 2020, 38, 602-604.	16.8	6
40	A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. <i>Cell</i> , 2020, 183, 347-362.e24.	28.9	349
41	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. <i>Cell</i> , 2020, 183, 818-834.e13.	28.9	287
42	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	28.9	206
43	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020, 11, 3800.	12.8	61
44	Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
45	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5701-5708.	7.0	133
46	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2020, 10, 1842-1853.	9.4	179
47	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108
48	Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. <i>Cancer Discovery</i> , 2020, 10, 1121-1128.	9.4	206
49	Protein-altering germline mutations implicate novel genes related to lung cancer development. <i>Nature Communications</i> , 2020, 11, 2220.	12.8	31
50	Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab. <i>Cancer Medicine</i> , 2020, 9, 4622-4631.	2.8	37
51	Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2020, 147, 1963-1969.	5.1	28
52	COVID-19 in patients with lung cancer. <i>Annals of Oncology</i> , 2020, 31, 1386-1396.	1.2	202
53	Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas. <i>Annals of Oncology</i> , 2020, 31, 599-608.	1.2	183
54	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. <i>Journal of Thoracic Oncology</i> , 2020, 15, 520-540.	1.1	119

#	ARTICLE	IF	CITATIONS
55	Clinical outcomes, local and regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2020, 149, 205-211.	0.6	39
56	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337.	7.0	90
57	Acquired Resistance to Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 37, 443-455.	16.8	444
58	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. , 2020, 8, e000147.		329
59	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	7.0	74
60	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1063-1069.	7.0	257
61	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. <i>Cell</i> , 2019, 178, 933-948.e14.	28.9	301
62	Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1784-1793.	1.1	232
63	Use of Circulating Tumor DNA for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6909-6915.	7.0	34
64	TOX is a critical regulator of tumour-specific T cell differentiation. <i>Nature</i> , 2019, 571, 270-274.	27.8	697
65	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. <i>Journal of Clinical Oncology</i> , 2019, 37, 3546-3555.	1.6	78
66	Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1794-1806.	1.1	69
67	Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2020-2031.	27.0	1,866
68	Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-8.	3.0	73
69	Treatment Outcomes of Immune-Related Cutaneous Adverse Events. <i>Journal of Clinical Oncology</i> , 2019, 37, 2746-2758.	1.6	160
70	EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 1311-1320.	1.2	249
71	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	1.6	811
72	Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5061-5068.	7.0	60

#	ARTICLE	IF	CITATIONS
73	Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 4663-4673.	7.0	210
74	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019, 25, 759-766.	30.7	180
75	Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> , 2019, 567, 479-485.	27.8	639
76	Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. <i>Annals of Oncology</i> , 2019, 30, 839-844.	1.2	256
77	Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors. <i>Annals of Oncology</i> , 2019, 30, 1134-1142.	1.2	113
78	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	10.7	137
79	First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. <i>Journal of Clinical Oncology</i> , 2019, 37, 992-1000.	1.6	457
80	Adding to the checkpoint blockade armamentarium. <i>Nature Medicine</i> , 2019, 25, 203-205.	30.7	5
81	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	7.0	179
82	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	3.0	58
83	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	3.0	26
84	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	1.1	241
85	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
86	Clinical Characterization of Immunotherapy-Related Pruritus Among Patients Seen in 2 Oncodermatology Clinics. <i>JAMA Dermatology</i> , 2019, 155, 249.	4.1	36
87	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Research</i> , 2019, 79, 1214-1225.	0.9	226
88	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2019, 111, 575-583.	6.3	96
89	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	27.0	1,495
90	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.	27.0	2,469

#	ARTICLE	IF	CITATIONS
91	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	16.8	827
92	PD-1/PD-L1 Axis in Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 15-19.	2.0	61
93	KEYNOTE-024: Unlocking a pathway to lung cancer cure?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1777-1780.	0.8	10
94	Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2018, 378, 158-168.	27.0	3,047
95	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	12.6	898
96	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	16.8	725
97	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. <i>Clinical Cancer Research</i> , 2018, 24, 3108-3118.	7.0	200
98	Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. <i>Science</i> , 2018, 359, 91-97.	12.6	3,689
99	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with <i>KRAS</i> -Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340.	7.0	323
100	Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. <i>Journal of Clinical Oncology</i> , 2018, 36, 1905-1912.	1.6	268
101	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1675-1684.	1.6	584
102	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2872-2878.	1.6	747
103	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	1.6	1,109
104	Acquired resistance to immunotherapy in MMR-D pancreatic cancer. , 2018, 6, 127.		27
105	Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 379, 1093-1094.	27.0	18
106	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	9.4	1,108
107	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. <i>Advances in Radiation Oncology</i> , 2018, 3, 391-398.	1.2	33
108	30 Immunotherapy in advanced NSCLC—from the “tsunami” of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). <i>ESMO Open</i> , 2018, 3, e000298.	4.5	10

#	ARTICLE	IF	CITATIONS
109	Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1363-1372.	1.1	140
110	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)., 2018, 6, 75.		188
111	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. <i>Cancer Immunology Research</i> , 2018, 6, 1093-1099.	3.4	258
112	Non-conventional Inhibitory CD4+Foxp3 ⁺ PD-1 ^{hi} T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	16.8	112
113	Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 169-169.	1.6	5
114	Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. <i>Cancer Immunology Research</i> , 2017, 5, 417-424.	3.4	400
115	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
116	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , The, 2017, 18, 31-41.	10.7	845
117	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017, 545, 452-456.	27.8	643
118	OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, S321-S322.	1.1	80
119	MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S393-S394.	1.1	20
120	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. <i>Cancer Discovery</i> , 2017, 7, 596-609.	9.4	490
121	Prognostic impact of TTF-1 expression in patients with stage IV lung adenocarcinomas. <i>Lung Cancer</i> , 2017, 108, 205-211.	2.0	42
122	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw260.	6.3	56
123	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	3.4	126
124	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. <i>Annals of Thoracic Surgery</i> , 2017, 104, e217-e218.	1.3	69
125	Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. <i>Nature Communications</i> , 2017, 8, 16078.	12.8	135
126	Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. <i>Immunity</i> , 2017, 47, 221-223.	14.3	31

#	ARTICLE	IF	CITATIONS
127	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. <i>Cell</i> , 2017, 171, 1284-1300.e21.	28.9	366
128	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. <i>Nature</i> , 2017, 551, 517-520.	27.8	532
129	Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, 709-717.	1.6	829
130	Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	3.0	9
131	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. <i>PLoS Medicine</i> , 2017, 14, e1002309.	8.4	256
132	Reply to M. Nishino et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1629-1630.	1.6	1
133	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
134	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 058). <i>Journal of Clinical Oncology</i> , 2017, 35, 1011-1020.	10.6	1,076
135	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. <i>PLoS ONE</i> , 2017, 12, e0182665.	2.5	54
136	Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2969-2979.	1.6	397
137	Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2980-2987.	1.6	444
138	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016, 130, 251-277.	2.2	107
139	Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2016, 11, 890-899.	1.1	4
140	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1048929.	0.7	31
141	Medians and Milestones in Describing the Path to Cancer Cures. <i>JAMA Oncology</i> , 2016, 2, 167.	7.1	40
142	Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial. <i>Journal of Thoracic Oncology</i> , 2016, 11, 537-544.	1.1	42
143	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. <i>Cancer Research</i> , 2016, 76, 999-1008.	0.9	451
144	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets. <i>Clinical Cancer Research</i> , 2016, 22, 3618-3629.	7.0	342

#	ARTICLE	IF	CITATIONS
145	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016, 351, 1463-1469.	12.6	2,445
146	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	27.0	5,183
147	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	12.6	6,756
148	Differences in the survival of patients with recurrent versus de novo metastatic KRAS mutant and EGFR mutant lung adenocarcinomas. <i>Cancer</i> , 2015, 121, 2078-2082.	4.1	15
149	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB / Clinical Oncology, 2015, 33, 2004-2012.	1.6	1,035
150	Genetics and immunology: reinvigorated. <i>Oncolmmunology</i> , 2015, 4, e1029705.	4.6	7
151	Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. <i>Clinical Lung Cancer</i> , 2015, 16, 514-522.	2.6	10
152	Chemotherapy for Lung Cancers: Here to Stay. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e375-e380.	3.8	4
153	Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1669-1674.	1.1	106
154	Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. <i>Lancet Oncology</i> , The, 2014, 15, e42-e50.	10.7	427
155	Opportunistic infections in patients treated with immunotherapy for cancer. , 2014, 2, 19.		98
156	Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. <i>Leukemia and Lymphoma</i> , 2014, 55, 538-543.	1.3	74
157	Clinical and in vivo Evidence that EGFR S768I Mutant Lung Adenocarcinomas Are Sensitive to Erlotinib. <i>Journal of Thoracic Oncology</i> , 2014, 9, e73-e74.	1.1	22
158	Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 453-461.	2.3	12
159	High Rate of Initial Treatment Failure in Patients with Primary Mediastinal B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2011, 118, 1601-1601.	1.4	1
160	The Estimated Magnitude and Direct Hospital Costs of Prosthetic Joint Infections in the United States, 1997 to 2004. <i>Journal of Arthroplasty</i> , 2010, 25, 766-771.e1.	3.1	36
161	Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. <i>Cancer</i> , 2010, 116, 4283-4290.	4.1	201